Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
暂无分享,去创建一个
M. Kurosaki | N. Izumi | Hiroaki Haga | K. Abe | Y. Ueno | H. Ohira | F. T. P. Group | J. Itakura | N. Sakamoto | M. Natsuizaka | S. Mochida | A. Takahashi | Masaru Baba | Yoshiya Yamamoto | T. Sho | Tomoe Kobayashi | K. Morikawa | I. Masakane | Koji Ogawa | Yoshihito Uchida | C. Hasebe | N. Kawagishi | G. Suda | M. Ohara | M. Nakai | Masami Abe | Ken Furuya | K. Kumagai | M. Umemura | Katsumi Terasita | A. Kawakami | Kenichi Morikawa | Masato Nakai | Masatsugu Ohara | Mitsuteru Natsuizaka
[1] Chih-Wei Lin,et al. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure , 2018, Hepatology.
[2] A. Tsubota,et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[3] N. Enomoto,et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection , 2017, Journal of Gastroenterology.
[4] H. Mo,et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. , 2017, Journal of Hepatology.
[5] A. Tsubota,et al. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy , 2017, Journal of Gastroenterology.
[6] K. Chayama,et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan , 2017, Journal of Gastroenterology.
[7] N. Sakamoto,et al. Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment , 2016, Journal of clinical and translational hepatology.
[8] T. Miyagishima,et al. Prevalence and characteristics of naturally occurring sofosbuvir resistance‐associated variants in patients with hepatitis C virus genotype 1b infection , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.
[9] H. Yoshiji,et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study , 2016, Journal of Gastroenterology.
[10] K. Reddy,et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. , 2016, Gastroenterology.
[11] T. Ishikawa,et al. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis , 2016, Journal of Gastroenterology.
[12] F. Sato,et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C , 2016, Journal of Gastroenterology.
[13] P. Messa,et al. Pegylated Interferon Mono‐Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta‐Analysis , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[14] D. Nelson,et al. Erratum: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 45 chronic kidney disease (the C-SURFER study): A combination phase 3 study. (Lancet (2015) 386 (1537-45)) , 2015 .
[15] T. Hassanein,et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.
[16] Shang-Jyh Hwang,et al. Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis , 2014, PloS one.
[17] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[18] N. Izumi,et al. 2011 Japanese Society for Dialysis Therapy Guidelines for the Treatment of Hepatitis C Virus Infection in Dialysis Patients , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[19] A. Macleod. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.
[20] K. Nitta,et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan , 2008, Clinical and Experimental Nephrology.
[21] B. Takkouche,et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta‐analysis of observational studies , 2007, Journal of viral hepatitis.
[22] S. Pol,et al. FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.
[23] S. Greenland,et al. Hepatitis C virus and death risk in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.
[24] N. Accortt,et al. Hepatitis C infection is acquired pre-ESRD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[25] R. Wolfe,et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.
[26] L. Seeff,et al. Natural history of chronic hepatitis C , 2002, Hepatology.
[27] F. Marumo,et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. , 2000, Journal of the American Society of Nephrology : JASN.